In summary, this study suggests that aberrant CDK5 activity promotes sporadic forms of MTC by modulating the expression of cell cycle proteins and points to these as possible biomarkers or targets for the development of new therapies. This evidence concerns the gene CDK5 and medullary thyroid gland carcinoma.